The selling of olestra.
The Procter & Gamble Company spent 30 years and an estimated $500 million to bring its non-digestible fat substitute, olestra, to market. The Food and Drug Administration approved olestra as a food additive but requires products containing olestra to carry a warning statement about its potential effects on gastrointestinal function. In obtaining approval for olestra, P&G conducted a lengthy, persistent, and comprehensive campaign to enlist support from members of Congress; FDA staff; and food, nutrition, and health professionals. This campaign raises larger questions about corporate influence on government policies, and the relationships of corporations to health professionals. To address these larger concerns, the author reviews the history of olestra's approval; describes P&G's campaign to obtain support from FDA and Congress, to defend olestra against critics, and to market it to professionals, the press, and consumers; and suggests implications for public health policies.
Nestle
M
M
Department of Nutrition and Food Studies, New York University, New York, NY 10012, USA. marion.nestle@nyu.edu
D000329:Advertising / Q000191:economics*; D016265:Conflict of Interest; D019358:Fat Substitutes / Q000009:adverse effects*; D005227:Fatty Acids / Q000009:adverse effects*; D019649:Food Industry / Q000191:economics; D005515:Food Labeling; D006801:Humans; D012955:Societies, Medical / Q000191:economics; D013395:Sucrose / Q000009:adverse effects / Q000031:analogs & derivatives*; D014481:United States; D014486:United States Food and Drug Administration
D019358:Fat Substitutes; D005227:Fatty Acids; D013395:Sucrose; C013692:sucrose polyester